Funding Opportunities

Title Announcement Number Activity Code Clinical Trials Status Expiration Date Sort descending Program Official
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research RFA-CA-24-009 (R33 Clinical Trial Not Allowed) R33 Clinical Trial Not Allowed 10/02/2024 Guillermo Marquez, Ph.D.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research RFA-CA-24-014 (P50 Clinical Trial Optional) P50 Clinical Trial Optional 10/02/2024 Guillermo Marquez, Ph.D.
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research RFA-CA-24-008 (R61 Clinical Trial Not Allowed) R61 Clinical Trial Not Allowed 10/02/2024 Guillermo Marquez, Ph.D.
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research RFA-CA-24-013 (U01 Clinical Trial Optional) U01 Clinical Trial Optional 10/02/2024 Guillermo Marquez, Ph.D.
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research RFA-CA-24-012 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 10/02/2024 Guillermo Marquez, Ph.D.
Notice of Special Interest: Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed) NOT-OD-22-202 Clinical Trial Not Allowed 04/16/2025 Nancy J. Emenaker, Ph.D., R.D.N., L.D., F.A.N.D.
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research PAR-22-099 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 05/08/2025 Richard Mazurchuk, Ph.D.
Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers NOT-CA-23-004 07/02/2025 Matthew Young, Ph.D.
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes PAR-22-131 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 09/08/2025 Richard Mazurchuk, Ph.D.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-23-313 (UH2/UH3 Clinical Trial Not Allowed) UH2, UH3 Clinical Trial Not Allowed 10/15/2026 Sudhir Srivastava, Ph.D., M.P.H.